Sullivan Cassidy

https://www.classactionlawyertn.com/xeljanz.html

After the ORAL Surveillance data emerged, analysts debated whether the FDA might take action either to remove Xeljanz from the market or – perhaps more likely – update its labelling to reflect the new data and leave prescribing decisions to do